- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04466475
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma
A Phase I Trial Evaluating Escalating Doses of 211At-Labeled Anti-CD38 Monoclonal Antibody (211At-OKT10-B10) Combined With Melphalan as Conditioning Prior to Autologous Hematopoietic Cell Transplantation for Patients With Multiple Myeloma
Study Overview
Status
Conditions
Detailed Description
OUTLINE: This is a dose-escalation study of 211At-OKT10-B10.
Patients receive 211At-OKT10-B10 intravenously (IV) continuously on day -10 to day - 4 (approximately day -7) and melphalan via infusion on day -2. Patients then undergo hematopoietic cell transplantation (HCT) on day 0.
After completion of study treatment, patients are followed for 30 days, between 80 and 90 days, at 6, 9, 12, 18, and 24 months, and then annually thereafter.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Damian J. Green
- Phone Number: 206-667-5398
- Email: dgreen@fredhutch.org
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with a diagnosis of multiple myeloma
- Patients must have autologous hematopoietic stem cells collected with a minimum CD34+ stem cell yield of >= 4 x 10^6 CD34+ cells/kg of body weight
- Subjects must have disease meeting criteria for clinical relapse or progressive disease (International Myeloma Working Group [IMWG] consensus criteria) and a history of >= 1 prior autologous stem cell transplant(s)
Subjects must have received at least 3 prior lines of therapy: an immunomodulatory drug, a proteasome inhibitor, and a CD38-targeting antibody
* Aline of therapy is defined as one or more cycles of a planned treatment program. This may consist of one or more planned cycles of a single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation, followed by maintenance is considered one line of therapy. A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a results of disease progression, relapse, or toxicity. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease
- Subjects must have an estimated creatinine clearance greater than 60 ml per minute by the following formula (Cockcroft-Gault). Serum creatinine value must be within 28 +/- days prior to registration
- Subjects must have an Eastern Cooperative Oncology Group (ECOG) score =< 2 or Karnofsky score >= 70%
- Ability to provide informed consent
- Subjects 18 years of age
Exclusion Criteria:
- Subjects with a history of plasma cell leukemia
- History of central nervous system involvement by multiple myeloma
- Prior radioimmunotherapy or radiation of > 20 Gy to pelvis or at maximally tolerated levels to any critical normal organ
- Prior allogeneic hematopoietic cell transplant
- More than 2 prior autologous hematopoietic cell transplants
- Subjects with medullary or extramedullary plasmacytoma/s measuring > 3 cm by magnetic resonance imaging (MRI) or positron emission tomography (PET)-computed tomography (CT) (radiated lesions are exempt from this criterion)
- Subjects with a history of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease as determined by the principal investigator (PI) or designee
- Subjects with corrected QT (QTc) prolongation at baseline
- Subjects with a history of cardiac arrhythmia and a heart rate > 100 beats per minute (BPM) (oral beta-blocker [excluding sotalol] and/or calcium channel blocker therapy are acceptable to achieve rate control)
- History of reactive airway disease and clinically significant asthma requiring any form of medical treatment in the prior three months
- Left ventricular ejection fraction < 40%
- Corrected diffusing capacity of the lungs for carbon monoxide (DLCO) < 50% or receiving supplemental continuous oxygen
- Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease.
- Bilirubin > 2 times the upper limit of normal
- Aspartate aminotransferase [AST] and alanine aminotransferase [ALT] > 2 times the upper limit of normal
- Subjects who are known to be seropositive for human immunodeficiency virus (HIV)
- Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin [HCG]+) or breast feeding
- Fertile subjects unwilling to use contraceptives during and for 12 months post-transplant
- Subjects with untreated and uncontrolled infection at time of enrollment
- Subjects with known amyloid light-chain (AL) subtype amyloidosis
- Known allergy to murine-based monoclonal antibodies
- Known contraindications to radiotherapy
- History of another primary malignancy that has not been in remission for at least 2 years (the following are exempt from the 2-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou [PAP] smear)
- Any anti-CD38 monoclonal antibody within 30 days of anticipated date of infusion of 211At-OKT10-B10
- Individuals with a history of CTCAE grade 4 gastrointestinal toxicity associated with prior high-dose melphalan conditioning therapy (previous autologous stem cell transplant)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (211At-OKT10-B10, melphalan, PBSC transplantation)
Patients receive 211At-OKT10-B10 IV continuously on day -10 to day - 4 (approximately day -7) and melphalan via infusion on day -2.
Patients then undergo HCT on day 0.
|
Given IV
Other Names:
Given via infusion
Other Names:
Undergo PBSC transplantation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose
Time Frame: Up to 30 days post-transplant
|
Defined a true dose limiting toxicity (DLT) probability of 25% of subjects, where a DLT is defined as any grade 3-5 nonhematologic regimen-related toxicity within the first 30 days following autologous hematopoietic cell transplantation.
|
Up to 30 days post-transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Achievement of response
Time Frame: Between days +80 to +90 post-transplant
|
Measured per the International Myeloma Working Group criteria.
The response rates (partial response [PR] or better) will be estimated along with the exact 95% confidence interval.
|
Between days +80 to +90 post-transplant
|
Duration of response
Time Frame: From response (PR or better) to disease relapse or death, assessed up to 5 years
|
Duration of response will be estimated using Kaplan-Meier methodology.
|
From response (PR or better) to disease relapse or death, assessed up to 5 years
|
Overall survival
Time Frame: From transplantation to death, assessed up to 2 years post-transplant
|
Kaplan-Meier methodology will be used to estimate the 2-year overall survival.
|
From transplantation to death, assessed up to 2 years post-transplant
|
Progression-free survival
Time Frame: From transplantation to disease relapse or death, assessed up to 2 years post-transplant
|
Kaplan-Meier methodology will be used to estimate the 2-year progression-free survival.
|
From transplantation to disease relapse or death, assessed up to 2 years post-transplant
|
Rates of minimal residual disease (MRD)
Time Frame: At days 28, and +80 to +90 post-transplant
|
MRD will be assessed using multi-color flow cytometry and next generation sequencing in conjunction with functional imaging (i.e., positron emission tomography-computed tomography).
The proportion who achieve MRD will be estimated along with an exact 95% confidence interval.
|
At days 28, and +80 to +90 post-transplant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Damian J. Green, Fred Hutch/University of Washington Cancer Consortium
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antibodies
- Immunoglobulins
- Daratumumab
- Melphalan
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
- Mechlorethamine
- Nitrogen Mustard Compounds
Other Study ID Numbers
- RG1006317
- NCI-2019-06979 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 10306 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
- R01CA205248 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plasma Cell Myeloma
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedRefractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell MyelomaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | ISS Stage I Plasma Cell MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)WithdrawnRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell LeukemiaUnited States
Clinical Trials on Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Not yet recruitingPlasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors | Metastatic Cancer | NeuroblastomaUnited States
-
Fred Hutchinson Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingNon-Malignant NeoplasmUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Plasma Cell MyelomaUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Janssen Research & Development, LLCActive, not recruitingClear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Bladder Urothelial Carcinoma | Metastatic Kidney Carcinoma | Malignant Urinary System NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedProstate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Testosterone Greater Than 150 ng/dLUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States